4.7 Review

Prevalence of Irritable Bowel Syndrome-type Symptoms in Patients With Celiac Disease: A Meta-analysis

期刊

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 11, 期 4, 页码 359-+

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2012.11.033

关键词

Abdominal Pain; Sprue; Bloating; Gluten Allergy

向作者/读者索取更多资源

BACKGROUND & AIMS: Patients with celiac disease (CD) often report symptoms compatible with irritable bowel syndrome (IBS). However, the prevalence of these symptoms in patients with CD and their relation to adherence to a gluten-free diet (GFD) have not been assessed systematically. METHODS: We searched MEDLINE, EMBASE, and EMBASE Classic (through July 2012) to identify cross-sectional surveys or case-control studies reporting prevalence of IBS-type symptoms in adult patients (>= 16 years old) with established CD. The number of individuals with symptoms meeting criteria for IBS was extracted for each study, according to case or control status and adherence to a GFD. Pooled prevalence and odds ratios (ORs), with 95% confidence intervals (CIs), were calculated. We analyzed data from 7 studies with 3383 participants. RESULTS: The pooled prevalence of IBS-type symptoms in all patients with CD was 38.0% (95% CI, 27.0%-50.0%). The pooled OR for IBS-type symptoms was higher in patients with CD than in controls (5.60; 95% CI, 3.23-9.70). In patients who were nonadherent with a GFD, the pooled OR for IBS-type symptoms, compared with those who were strictly adherent, was 2.69 (95% CI, 0.75-9.56). There was also a trend toward a higher OR for IBS-type symptoms among patients who did not adhere to the GFD, compared with controls (12.42; 95% CI, 6.84-11.75), compared with that observed for adherent CD patients vs controls (4.28; 95% CI, 1.56-11.75). CONCLUSIONS: IBS-type symptoms occur frequently in patients with CD and are more common than among controls. Adherence to a GFD might be associated with a reduction in symptoms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Gastroenterology & Hepatology

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis

Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford

Summary: This study conducted a network meta-analysis to compare the relative efficacy of various biological therapies and small molecules in the treatment of luminal Crohn's disease. The results showed differences in the effectiveness of different drugs in inducing and maintaining clinical remission, and previous exposure to biologics also had an impact on treatment outcomes.
Letter Gastroenterology & Hepatology

Immortal time bias in a retrospective study examining colorectal cancer mortality according to adherence to colonoscopy

Conchubhair Winters, Alexander Charles Ford

Review Gastroenterology & Hepatology

Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis

Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford

Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Article Gastroenterology & Hepatology

Willingness to pay for medications among patients with Rome IV irritable Bowel syndrome

Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

Summary: This study examined willingness to pay for medications among individuals with irritable bowel syndrome (IBS). The results showed that women and individuals with an annual income of 30,000 pounds or more were more likely to be willing to pay for medication. In addition, individuals with lower IBS-related quality of life were more willing to pay for a medication that could improve their symptoms.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Review Gastroenterology & Hepatology

Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford

Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome

Vivek C. C. Goodoory, Elspeth A. A. Guthrie, Cho E. E. Ng, Christopher J. J. Black, Alexander C. C. Ford

Summary: Irritable bowel syndrome (IBS) has a substantial impact on the quality of life of affected individuals, and the negative impact is worse than observed in some severe chronic organic conditions.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Gastroenterology & Hepatology

Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis

Maria Rosa Ingrosso, Michael Camilleri, Jan Tack, Gianluca Ianiro, Christopher J. Black, Alexander C. Ford

Summary: This study evaluated the efficacy and safety of drugs for gastroparesis through a network meta-analysis. The results showed that oral dopamine antagonists and tachykinin-1 antagonists were more effective than placebo. For individual symptoms, oral metoclopramide showed good efficacy for nausea, fullness, and bloating. However, the confidence in the evidence for most comparisons was low to moderate, indicating a need for more effective therapies for gastroparesis.

GASTROENTEROLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply

Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Substantial Variability in Placebo and Nocebo Responses Challenges the Validity of Network Meta-Analysis of Gastroparesis Pharmacotherapy Reply

Maria rosa Ingrosso, Christopher j. Black, Alexander c. Ford

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study

Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford

Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply

Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Gastroenterology & Hepatology

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford

Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.

GASTROENTEROLOGY (2023)

Review Gastroenterology & Hepatology

Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis

Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford, Edoardo Savarino

Summary: A network meta-analysis was conducted to compare the efficacy of different drugs for active eosinophilic esophagitis (EoE). The results showed that most available drugs were more effective than placebo in treating EoE. However, significant heterogeneity among the trials hindered the establishment of a solid therapeutic hierarchy.
Article Gastroenterology & Hepatology

Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study

Christy Riggott, Keeley M. Fairbrass, Christian P. Selinger, David J. Gracie, Alexander C. Ford

Summary: The use of opioids in patients with inflammatory bowel disease (IBD) is associated with psychological comorbidity and an increased risk of intestinal resection, particularly with stronger formulations. Future studies should classify the risks of different opioids to develop reliable prescribing algorithms, and evaluate the effectiveness of addressing psychological factors as an opioid avoidance strategy in routine IBD care.

INFLAMMATORY BOWEL DISEASES (2023)

Meeting Abstract Gastroenterology & Hepatology

Longitudinal follow-up study to determine durability of a diagnosis of Rome IV Irritable bowel syndrome in secondary care

Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford

暂无数据